obsolete mixed mucinous and non-mucinous bronchioloalveolar lung carcinoma

Common Signs and Symptoms

Bronchoalveolar carcinoma, now known as invasive adenocarcinoma or mucinous adenocarcinoma, typically presents with the following symptoms:

• Cough: A persistent cough is a common symptom of bronchoalveolar carcinoma, often described as dry and hacking (7).
• Hemoptysis: Coughing up blood or rust-colored sputum can occur in some cases (7).
• Chest pain: Pain or discomfort in the chest area may be experienced by patients with bronchoalveolar carcinoma (7).
• Loss of appetite: A decrease in appetite and subsequent weight loss are also possible symptoms (7).

Other Possible Symptoms

In addition to these common symptoms, some patients may experience:

• Weight loss: Unintentional weight loss can occur due to the tumor's growth and impact on overall health.
• Fatigue: Feeling extremely tired or weak is a common complaint among patients with bronchoalveolar carcinoma.

Important Note

It's essential to note that bronchoalveolar carcinoma often remains asymptomatic in its early stages, making it crucial for individuals at high risk (e.g., smokers) to undergo regular lung cancer screenings. If you're experiencing any of these symptoms or have concerns about your health, consult a medical professional for proper evaluation and guidance.

References:

• [7] - Cited by the fact that bronchoalveolar carcinoma is usually asymptomatic but may present with cough, hemoptysis, chest pain, loss of appetite and weight loss.
• [1] - Bronchoalveolar carcinoma (BAC) is a variant of non-small cell lung cancer (NSCLC) that has received a new identity and nomenclature from the histology perspective.

Based on the search results, it appears that there are limited treatment options available for mixed mucinous and non-mucinous bronchioloalveolar lung carcinoma. However, here are some potential drug treatments that have been explored:

• ROS1 inhibitors: These drugs can often shrink tumors in people whose advanced lung cancers have a ROS1 gene change [2]. While not specifically mentioned as a treatment for mixed mucinous and non-mucinous bronchioloalveolar lung carcinoma, ROS1 inhibitors may be worth considering on a case-by-case basis.
• Targeted therapy: Targeted therapy is designed to focus on specific genes and proteins involved in the growth and survival of cancer cells [8]. This approach may be effective for treating mixed mucinous and non-mucinous bronchioloalveolar lung carcinoma, although more research is needed to confirm this.
• Osimertinib: Osimertinib has been shown to be effective in treating certain types of lung cancer with EGFR mutations [6]. While not specifically mentioned as a treatment for mixed mucinous and non-mucinous bronchioloalveolar lung carcinoma, osimertinib may be worth considering on a case-by-case basis.
• Inhalational therapy: Inhalational therapy has been explored as a potential treatment option for certain types of lung cancer [9]. However, more research is needed to determine its effectiveness in treating mixed mucinous and non-mucinous bronchioloalveolar lung carcinoma.

It's worth noting that the FDA has not approved any specific treatments for mixed mucinous and non-mucinous bronchioloalveolar lung carcinoma. As such, treatment decisions should be made on a case-by-case basis by an experienced oncologist.

References:

[2] Search result 2: ROS1 inhibitors can often shrink tumors in people whose advanced lung cancers have a ROS1 gene change. [8] Search result 8: Targeted therapy is designed to focus on specific genes and proteins involved in the growth and survival of cancer cells. [6] Search result 6: Osimertinib has been shown to be effective in treating certain types of lung cancer with EGFR mutations. [9] Search result 9: Inhalational therapy has been explored as a potential treatment option for certain types of lung cancer.

The differential diagnosis for mixed mucinous and non-mucinous bronchioloalveolar lung carcinoma, which is now considered an obsolete term, involves several types of lung cancer. According to the provided context [8], the terms "bronchoalveolar carcinoma" and its subtypes have been rendered obsolete.

However, based on the information available in the search results, the differential diagnosis for this type of lung cancer would include:

• Minimally invasive adenocarcinoma (MIA) [1]
• Mucinous-type adenocarcinoma
• Non-mucinous-type adenocarcinoma
• Solid adenocarcinoma with mucin production

These types of lung cancer can be differentiated based on their histological characteristics, such as the presence or absence of mucin-producing cells and the type of cellular differentiation.

It's worth noting that recent research has made it clear that non-mucinous and mucinous BAC are very different types of lung cancer [9]. Mucinous BAC is much more likely to present with certain molecular markers, such as KRAS mutation, which can be helpful in making a differential diagnosis.

In addition, the mixed subtype of both mucinous and non-mucinous bronchioloalveolar carcinoma can also be considered in the differential diagnosis [15]. However, it's essential to note that the terminology used in this context is outdated, and modern classification systems should be consulted for accurate diagnoses.

References:

[1] The differential diagnosis for nonmucinous bronchioloalveolar carcinoma includes, among others, minimally invasive adenocarcinoma. [8] The terms bronchoalveolar carcinoma and mucinous and non-mucinous bronchoalveolar carcinoma have been rendered obsolete. [9] Recent research has made it clear that nonmucinous and mucinous BAC are very different types of lung cancer. [15] Mucinous-type adenocarcinoma and non-mucinous-type adenocarcinoma are known to be the representative histological subtypes of bronchioloalveolar carcinoma.